Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) — The “Pharmaceutical Drug Delivery Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031” has been added to ResearchAndMarkets.com’s offering.
The Global Pharmaceutical Drug Delivery Market is projected to expand from a valuation of USD 2.12 Billion in 2025 to USD 2.97 Billion by 2031, reflecting a CAGR of 5.76%.
This sector is defined by specialized systems and formulations designed to transport therapeutic agents to targeted physiological sites, thereby ensuring maximum medical efficacy. The market is primarily underpinned by the increasing global incidence of chronic diseases and the burgeoning biologics sector, which demands precise administration techniques beyond conventional oral routes. Illustrating the significant capital driving these advanced technologies, the European Federation of Pharmaceutical Industries and Associations estimated in 2024 that the research-based pharmaceutical industry invested €55.00 billion in R&D across Europe.
However, the market faces considerable obstacles due to the rigorous regulatory framework governing new delivery vehicles and combination products. The approval process for advanced systems, such as nanotechnology-based carriers, is intricate, often requiring extensive clinical validation and incurring exorbitant development costs. These regulatory demands create high barriers to entry and can significantly postpone commercialization, potentially hindering the rapid introduction of innovative delivery solutions to the global landscape.
Market Drivers
The escalating burden of chronic and non-communicable diseases acts as a major catalyst for the global drug delivery market, necessitating the deployment of targeted and sustained-release mechanisms. In the field of oncology, there is an intensifying demand for antibody-drug conjugates and nanoparticle carriers to enhance therapeutic indices.
According to the American Cancer Society’s ‘Cancer Facts & Figures 2024’, released in January 2024, new cancer diagnoses in the United States are projected to exceed 2 million for the first time, underscoring the critical need for precision delivery systems. This epidemiological shift compels manufacturers to focus on developing formulations and devices that ensure medication adherence and efficacy for long-term management.
Simultaneously, the sector is being propelled by increased R&D investments in complex drug formulation and lifecycle management, particularly to support the expanding biologics pipeline. Pharmaceutical companies are allocating substantial capital to resolve stability and bioavailability challenges associated with large-molecule therapeutics through innovative delivery vehicles.
As per the ‘2024 PhRMA Annual Membership Survey’ published in September 2024, member companies reported a record-high $103.1 billion investment in research and development during 2023, a financial commitment that accelerates the commercialization of advanced technologies. Furthermore, the U.S. Food and Drug Administration noted in 2024 that the Center for Drug Evaluation and Research approved 55 novel therapeutics in the preceding year, significantly broadening the landscape of products requiring specialized administration.
Market Challenges
The stringent regulatory landscape regarding novel delivery vehicles constitutes a primary restraint on the growth of the global pharmaceutical drug delivery market. Regulatory bodies enforce rigorous standards for combination products and advanced carriers, requiring manufacturers to conduct extensive and prolonged clinical trials to demonstrate safety and efficacy.
This complex approval process extends development timelines significantly, delaying the commercial availability of new delivery systems. Consequently, companies face prolonged periods of uncertainty and delayed return on investment, which discourages the pursuit of high-risk innovative projects and limits the volume of new products entering the market.
These regulatory hurdles directly translate into substantial financial burdens, creating a high barrier to entry that hampers market expansion. The necessity for comprehensive validation data forces manufacturers to allocate immense resources to the research phase, often making development financially unviable for smaller entities.
According to the Pharmaceutical Research and Manufacturers of America, in 2024, member companies reported a record research and development expenditure of $103.5 billion, reflecting the escalating costs associated with navigating these demanding development pathways. This intense financial pressure restricts the ability of market players to introduce diverse solutions rapidly, thereby slowing the overall trajectory of the sector.
Market Trends
The proliferation of wearable on-body injectors for chronic conditions is fundamentally reshaping the administration landscape by enabling patients to manage complex therapies outside clinical settings. Unlike traditional parenteral methods, these discreet, tubeless systems offer continuous subcutaneous delivery of large-volume biologics, directly addressing the need for lifestyle-compatible treatment options.
This shift is particularly evident in the diabetes management sector, where the demand for automated delivery systems is surging. According to Insulet Corporation’s ‘Third Quarter 2024 Financial Results’ from November 2024, the company reported quarterly revenue of $543.9 million, a 25.7% increase year-over-year, driven largely by the rapid adoption of its Omnipod 5 automated insulin delivery system, indicating a broader industry move toward devices that combine medication storage and propulsion into a single, patient-friendly unit.
The adoption of connected smart devices for adherence monitoring represents a pivotal convergence of digital health and medication delivery technologies. Manufacturers are increasingly embedding connectivity features such as Bluetooth and sensor technology into delivery systems to capture real-time dosing data, thereby enhancing patient compliance and providing actionable insights for healthcare providers.
This integration allows for the creation of closed-loop ecosystems where administration devices communicate directly with mobile applications to automate dosage tracking and algorithmic adjustments. According to Ypsomed Holding AG’s ‘Semiannual Report 2024/25’ released in November 2024, the company’s mylife Loop solution, which connects an insulin pump to a smartphone-based algorithm, reached approximately 60,000 users by the end of September 2024, underscoring the market’s evolution from simple mechanical tools to intelligent data-generating platforms that optimize therapeutic outcomes.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 185 |
| Forecast Period | 2025 – 2031 |
| Estimated Market Value (USD) in 2025 | $2.12 Billion |
| Forecasted Market Value (USD) by 2031 | $2.97 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Global |
Report Scope:
Key Players Profiled in the Pharmaceutical Drug Delivery Market:
- Johnson & Johnson
- Novartis International AG
- F. Hoffmann-La Roche AG
- Pfizer Inc.
- Bayer AG
- Antares Pharma, Inc.
- Becton, Dickinson and Company
- GlaxoSmithKline PLC
- Merck & Co., Inc.
- Amgen, Inc.
- AbbVie Inc.
Pharmaceutical Drug Delivery Market, by Route of Administration:
- Oral drug delivery
- Nasal drug delivery
- Ocular drug delivery
- Topical drug delivery
- Others
Pharmaceutical Drug Delivery Market, by Application:
- Cancer
- Infectious Diseases
- Diabetes
- Cardiovascular Diseases
- Others
Pharmaceutical Drug Delivery Market, by Region:
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
For more information about this report visit https://www.researchandmarkets.com/r/kzmp00
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Pharmaceutical Drug Delivery Market
